PIN1 and acute promyelocytic leukemia: Pin1 inhibitor ATRA is used in clinical to treat APL, but shows detectable but not striking anticancer activity against solid tumors30, 31, 32, very likely due to its light sensitivity and short half life of 45 min in humans33, 52, 53.